Additionally, we proposed pulmonary delivery of a third-generation CB1R antagonist (a dual peripheral CB1R/iNOS antagonist) as an effective and safe therapeutic modality in PF using the bleomycin-induced PF model. This evidence concerns the gene NOS2 and pemphigus foliaceus.